GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Cyclically Adjusted Revenue per Share

Traws Pharma (FRA:0T2) Cyclically Adjusted Revenue per Share : €175.39 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Traws Pharma's adjusted revenue per share for the three months ended in Dec. 2023 was €0.002. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €175.39 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Traws Pharma's average Cyclically Adjusted Revenue Growth Rate was -25.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-15), Traws Pharma's current stock price is €0.59. Traws Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €175.39. Traws Pharma's Cyclically Adjusted PS Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Traws Pharma was 0.01. The lowest was 0.01. And the median was 0.01.


Traws Pharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Traws Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Cyclically Adjusted Revenue per Share Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 887.15 248.11 175.39

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 248.11 233.07 207.56 214.13 175.39

Competitive Comparison of Traws Pharma's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Cyclically Adjusted PS Ratio falls into.



Traws Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Traws Pharma's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.002/129.4194*129.4194
=0.002

Current CPI (Dec. 2023) = 129.4194.

Traws Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 323.000 99.695 419.306
201406 92.000 100.560 118.403
201409 88.000 100.428 113.404
201412 92.000 99.070 120.184
201503 105.000 99.621 136.407
201506 110.000 100.684 141.394
201509 1,445.000 100.392 1,862.817
201512 8,810.000 99.792 11,425.569
201603 1,324.000 100.470 1,705.490
201606 2,001.000 101.688 2,546.691
201609 735.500 101.861 934.489
201612 82.000 101.863 104.183
201703 98.000 102.862 123.302
201706 96.000 103.349 120.216
201709 30.667 104.136 38.113
201712 40.333 104.011 50.186
201803 114.250 105.290 140.433
201806 23.056 106.317 28.066
201809 4.120 106.507 5.006
201812 2.080 105.998 2.540
201903 2.308 107.251 2.785
201906 68.808 108.070 82.402
201909 2.111 108.329 2.522
201912 0.055 108.420 0.066
202003 0.066 108.902 0.078
202006 0.004 108.767 0.005
202009 0.005 109.815 0.006
202012 0.004 109.897 0.005
202103 0.003 111.754 0.003
202106 0.003 114.631 0.003
202109 0.003 115.734 0.003
202112 0.002 117.630 0.002
202203 0.002 121.301 0.002
202206 0.003 125.017 0.003
202209 0.003 125.227 0.003
202212 0.003 125.222 0.003
202303 0.002 127.348 0.002
202306 0.003 128.729 0.003
202309 0.003 129.860 0.003
202312 0.002 129.419 0.002

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Traws Pharma  (FRA:0T2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Traws Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.59/175.39
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Traws Pharma was 0.01. The lowest was 0.01. And the median was 0.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Traws Pharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (FRA:0T2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines